Customized phage therapies to eradicate
harmful bacteria in chronic diseases
Featured Highlights
BiomX News
BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin
- Primary endpoints are safety and tolerability - Exploratory endpoints include proof of principle by measurement of C. acnes skin levels - Clinical data are expected at the end of the first quarter of 2020 Ness Ziona, Israel – Dec. 2, 2019 – BiomX Inc. (NYSE: PHGE),...
BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis
- Data presented at the presidential plenary translational session of the AASLD conference - Results demonstrate in vivo use of a phage cocktail effectively eradicated a bacteria hypothesized to be a disease modifying target in Primary Sclerosing Cholangitis (PSC)...
BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director
Ness Ziona, Israel – November 4, 2019, – BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies, today announced the election of Russell G. Greig, Ph.D., as Chairman of the Board of Directors and Lynne Sullivan as Board...
OUR INVESTORS
